AU674339B2 - Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway - Google Patents

Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway Download PDF

Info

Publication number
AU674339B2
AU674339B2 AU48403/93A AU4840393A AU674339B2 AU 674339 B2 AU674339 B2 AU 674339B2 AU 48403/93 A AU48403/93 A AU 48403/93A AU 4840393 A AU4840393 A AU 4840393A AU 674339 B2 AU674339 B2 AU 674339B2
Authority
AU
Australia
Prior art keywords
human
cells
rna
expression
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48403/93A
Other languages
English (en)
Other versions
AU4840393A (en
Inventor
Jiali Gu
Jerry L Nadler
Rama Devi Natarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of AU4840393A publication Critical patent/AU4840393A/en
Application granted granted Critical
Publication of AU674339B2 publication Critical patent/AU674339B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11012—Linoleate 13S-lipoxygenase (1.13.11.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11031—Arachidonate 12-lipoxygenase (1.13.11.31), i.e. lipoxygenase-type-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU48403/93A 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway Ceased AU674339B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93666092A 1992-08-28 1992-08-28
US936660 1992-08-28
PCT/US1993/008106 WO1994005777A1 (fr) 1992-08-28 1993-08-26 Inhibition de la formation ou de l'activite du processus de 12-lipoxygenase dans les leucocytes humains

Publications (2)

Publication Number Publication Date
AU4840393A AU4840393A (en) 1994-03-29
AU674339B2 true AU674339B2 (en) 1996-12-19

Family

ID=25468927

Family Applications (2)

Application Number Title Priority Date Filing Date
AU48403/93A Ceased AU674339B2 (en) 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway
AU70906/94A Abandoned AU7090694A (en) 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU70906/94A Abandoned AU7090694A (en) 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof

Country Status (5)

Country Link
EP (2) EP0621895A4 (fr)
JP (1) JPH07500254A (fr)
AU (2) AU674339B2 (fr)
CA (1) CA2077461C (fr)
WO (2) WO1994005777A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191169B1 (en) 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1996034943A1 (fr) * 1995-05-04 1996-11-07 City Of Hope 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
AUPP349098A0 (en) * 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6582957B1 (en) 1999-04-12 2003-06-24 Lexicon Genetics Incorporated Lipoxygenase proteins and polynucleotides encoding the same
CN1301847A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——脂肪氧化酶10和编码这种多肽的多核苷酸
CN1313389A (zh) * 2000-03-15 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人脂肪氧化酶9和编码这种多肽的多核苷酸

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849445A (en) * 1983-12-14 1989-07-18 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
JPH0815851B2 (ja) * 1987-10-09 1996-02-21 日産自動車株式会社 差動制限装置

Also Published As

Publication number Publication date
EP0621895A4 (en) 1996-11-27
EP0696193A1 (fr) 1996-02-14
EP0696193A4 (fr) 1996-11-27
EP0621895A1 (fr) 1994-11-02
JPH07500254A (ja) 1995-01-12
AU4840393A (en) 1994-03-29
CA2077461A1 (fr) 1994-03-01
AU7090694A (en) 1995-08-01
WO1995018609A1 (fr) 1995-07-13
WO1994005777A1 (fr) 1994-03-17
CA2077461C (fr) 2000-02-15

Similar Documents

Publication Publication Date Title
Usala et al. A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds.
Mizuno et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
Ruan et al. Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet.
Buchaille et al. A substractive PCR-based cDNA library from human odontoblast cells: identification of novel genes expressed in tooth forming cells
US20040018528A1 (en) Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2002083866A2 (fr) Sequences repetees du gene ca125 et leurs utilisations dans des interventions diagnostiques et therapeutiques
Ishikawa et al. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats
Hansen et al. Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM
US6551812B1 (en) Compositions and methods relating to the peroxisomal proliferator activated receptor-α mediated pathway
AU674339B2 (en) Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway
US20060057628A1 (en) Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
US20040235006A1 (en) Chemical compounds
Nanji et al. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat
Press et al. Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor β
Yoshida et al. Biological Role of Human Cytosolic Aldehyde Dehygrogenase 1: Hormonal Response, Retinal Oxidation and Implication in Testicular Feminization
EP1954832A2 (fr) Procédés de diagnostique de sensibilité à la douleur et chronicité de douleur et procédés destinés aux troubles liés à la tétrahydrobiopterine
EP1469084A2 (fr) Polymorphismes dans le gène humain de KDR
EP1054066A2 (fr) Procédé pour anticiper la sensitibilité d'un médicament contre l'ostéoporose et une substance appropriée
JP2012502105A (ja) イロペリドンの投与方法
US8361728B2 (en) Method for diagnosis of glutamate dehydrogenase disorders
JP2002523111A (ja) 特定医薬を代謝することに対する患者の能力を測定する方法
FR2824333A1 (fr) Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
Kakiki et al. Expression of aldosterone synthase cytochrome P450 (P450aldo) mRNA in rat adrenal glomerulosa cells by angiotensin ii type1 receptor
CA2278502A1 (fr) Methodes genetiques permettant d'identifier des individus en vue d'ameliorer leur bien-etre et leur performance par des exercices
JP4169143B2 (ja) 代謝酵素ｃｙｐ２ｃ８の多型を利用した薬物代謝の検査方法および検査薬、並びに、薬物代謝を改善する化合物のスクリーニング方法